Monitoring response to therapy for patients with chronic myeloid leukemia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chronic myeloid leukemia (CML) has become a model in cancer medicine for how advances in understanding of the biology of the disease can be translated into the characterization of targets for therapy and how these same targets can be used effectively as molecular markers in the diagnosis and monitoring of the patient ' s response to therapy. In the 1990 s, treatment options available for CML patients were hydroxyurea, busulfan, interferon alfa (IFNα) with or without low-dose cytosine arabinoside, and allogeneic stem cell transplant. Introduction of imatinib mesylate in 1998, revolutionalized treatment of CML. Improvement in treatments necessitates improvement in monitoring of minimal residual disease (MRD) and the past three decades have witnessed significant changes in monitoring of CML patients on therapy.

LanguageEnglish
Title of host publicationChronic Myeloproliferative Disorders
PublisherCRC Press
Pages103-117
Number of pages15
ISBN (Electronic)9780203091616
ISBN (Print)9780415415989
Publication statusPublished - 1 Jan 2008

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hiwase, D., & Hughes, T. (2008). Monitoring response to therapy for patients with chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 103-117). CRC Press.
Hiwase, Devendra ; Hughes, Timothy. / Monitoring response to therapy for patients with chronic myeloid leukemia. Chronic Myeloproliferative Disorders. CRC Press, 2008. pp. 103-117
@inbook{5191b5a75e804561b194fe9ab22a1379,
title = "Monitoring response to therapy for patients with chronic myeloid leukemia",
abstract = "Chronic myeloid leukemia (CML) has become a model in cancer medicine for how advances in understanding of the biology of the disease can be translated into the characterization of targets for therapy and how these same targets can be used effectively as molecular markers in the diagnosis and monitoring of the patient ' s response to therapy. In the 1990 s, treatment options available for CML patients were hydroxyurea, busulfan, interferon alfa (IFNα) with or without low-dose cytosine arabinoside, and allogeneic stem cell transplant. Introduction of imatinib mesylate in 1998, revolutionalized treatment of CML. Improvement in treatments necessitates improvement in monitoring of minimal residual disease (MRD) and the past three decades have witnessed significant changes in monitoring of CML patients on therapy.",
author = "Devendra Hiwase and Timothy Hughes",
year = "2008",
month = "1",
day = "1",
language = "English",
isbn = "9780415415989",
pages = "103--117",
booktitle = "Chronic Myeloproliferative Disorders",
publisher = "CRC Press",

}

Hiwase, D & Hughes, T 2008, Monitoring response to therapy for patients with chronic myeloid leukemia. in Chronic Myeloproliferative Disorders. CRC Press, pp. 103-117.

Monitoring response to therapy for patients with chronic myeloid leukemia. / Hiwase, Devendra; Hughes, Timothy.

Chronic Myeloproliferative Disorders. CRC Press, 2008. p. 103-117.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Monitoring response to therapy for patients with chronic myeloid leukemia

AU - Hiwase, Devendra

AU - Hughes, Timothy

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Chronic myeloid leukemia (CML) has become a model in cancer medicine for how advances in understanding of the biology of the disease can be translated into the characterization of targets for therapy and how these same targets can be used effectively as molecular markers in the diagnosis and monitoring of the patient ' s response to therapy. In the 1990 s, treatment options available for CML patients were hydroxyurea, busulfan, interferon alfa (IFNα) with or without low-dose cytosine arabinoside, and allogeneic stem cell transplant. Introduction of imatinib mesylate in 1998, revolutionalized treatment of CML. Improvement in treatments necessitates improvement in monitoring of minimal residual disease (MRD) and the past three decades have witnessed significant changes in monitoring of CML patients on therapy.

AB - Chronic myeloid leukemia (CML) has become a model in cancer medicine for how advances in understanding of the biology of the disease can be translated into the characterization of targets for therapy and how these same targets can be used effectively as molecular markers in the diagnosis and monitoring of the patient ' s response to therapy. In the 1990 s, treatment options available for CML patients were hydroxyurea, busulfan, interferon alfa (IFNα) with or without low-dose cytosine arabinoside, and allogeneic stem cell transplant. Introduction of imatinib mesylate in 1998, revolutionalized treatment of CML. Improvement in treatments necessitates improvement in monitoring of minimal residual disease (MRD) and the past three decades have witnessed significant changes in monitoring of CML patients on therapy.

UR - http://www.scopus.com/inward/record.url?scp=85056503415&partnerID=8YFLogxK

M3 - Chapter

SN - 9780415415989

SP - 103

EP - 117

BT - Chronic Myeloproliferative Disorders

PB - CRC Press

ER -

Hiwase D, Hughes T. Monitoring response to therapy for patients with chronic myeloid leukemia. In Chronic Myeloproliferative Disorders. CRC Press. 2008. p. 103-117